View clinical trials related to Leukemia, Myeloid.
Filter by:Single patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.
The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.
This program provides access to asciminib for patients with CML in chronic phase (CP) without documented T315I mutation after failure to or intolerance of two prior TKI OR patients in CML-CP with documented T315I mutation and without comparable or satisfactory alternative therapy to treat the disease